Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT05553093
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Registry
-
NCT05553093
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT05553093. Randomized; no masking; primary purpose treatment. Start 2022-03-15 (actual); primary completion 2023-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
Record details
- Record id
cardio:ct-nct05553093- Content hash
2a80b5f1418000645eeb9f835187a6131c6585faf10130612962566c5c623b0c